Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
A Phase 1B, Multi-Center, Randomized, Placebo-Controlled Trial of Inhaled Seralutinib in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)